Adriana Ceballos-Gutiérrez

Dr. Adriana Ceballos-Gutiérrez

Universidad de Colima, Colima, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Adriana Ceballos-GutiérrezAdriana Ceballos-Gutiérrez
Adriana Ceballos-Gutiérrez
ARAlejandrina Rodríguez-Hernández
Alejandrina Rodríguez-Hernández
MÁMaría del Rosario Álvarez-Valadez
María del Rosario Álvarez-Valadez
SLSarai Limon-Miranda
Sarai Limon-Miranda
FAFelipa Andrade
Felipa Andrade
Adolfo Virgen-OrtizAdolfo Virgen-Ortiz
Adolfo Virgen-Ortiz
ZnO nanoparticles (ZnONPs) have been shown to have therapeutic potential in some diseases such as diabetes and cancer. However, concentration-dependent adverse effects have also been reported. Studies which evaluate the effects of ZnONPs on the cardiovascular system are scarce. This study aimed to evaluate the cardiovascular effects of a low dose of ZnONPs administered chronically in healthy rats. Changes in dyslipidemia biomarkers, blood pressure, aortic wall structure, vascular contractility, and expression of cannabinoid receptors in the aorta wall were evaluated. Healthy rats were divided into two groups: control or treated (one, two, and three months). The treated rats received an oral dose of 10 mg/kg/day. The results showed that treatment with ZnONPs induced dyslipidemia from the first month, increasing atherosclerosis risk, which was confirmed by presence of atherosclerotic alterations revealed by aorta histological analysis. In in vitro assays, ZnONPs modified the aorta contractile activity in response to the activation of cannabinoid receptors (CB1 and CB2). The expression of CB1 and CB2 was modified as well. Moreover, ZnONPs elicited an increase in blood pressure. In conclusion, long-time oral administration of ZnONPs induce dyslipidemia and atherosclerosis eliciting alterations in aorta contractility, CB1 and CB2 receptors expression, and an increase in blood pressure in healthy rats.